hydroxychloroquine has been researched along with Macrophage Activation Syndrome in 5 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Macrophage Activation Syndrome: A serious complication of childhood systemic inflammatory disorders that is thought to be caused by excessive activation and proliferation of T-LYMPHOCYTES and MACROPHAGES. It is seen predominantly in children with systemic onset JUVENILE IDIOPATHIC ARTHRITIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Admission Systemic Lupus Erythematosus Disease Activity Index scores (30 vs." | 5.48 | Arthritis and use of hydroxychloroquine associated with a decreased risk of macrophage activation syndrome among adult patients hospitalized with systemic lupus erythematosus. ( Cohen, EM; Costenbader, KH; D'Silva, K; Kreps, D; Son, MB, 2018) |
| "This can be independent from coronavirus disease 2019 gravity." | 2.66 | Macrophage activation syndrome as an unusual presentation of paucisymptomatic severe acute respiratory syndrome coronavirus 2 infection: A case report. ( Calmy, A; Coen, M; Lolachi, S; Morin, S; Samii, K; Serratrice, J, 2020) |
| "Admission Systemic Lupus Erythematosus Disease Activity Index scores (30 vs." | 1.48 | Arthritis and use of hydroxychloroquine associated with a decreased risk of macrophage activation syndrome among adult patients hospitalized with systemic lupus erythematosus. ( Cohen, EM; Costenbader, KH; D'Silva, K; Kreps, D; Son, MB, 2018) |
| "We describe a case of MAS secondary to systemic lupus erythematosus in a young female that responded well to rituximab in lieu of etoposide." | 1.46 | Novel use of rituximab in macrophage activation syndrome secondary to systemic lupus erythematosus. ( Junga, Z; Keith, M; Stitt, R; Tracy, C, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Phoophiboon, V | 1 |
| Brown, P | 1 |
| Burns, KEA | 1 |
| Lolachi, S | 1 |
| Morin, S | 1 |
| Coen, M | 1 |
| Samii, K | 1 |
| Calmy, A | 1 |
| Serratrice, J | 1 |
| Fanouriakis, A | 1 |
| Tziolos, N | 1 |
| Bertsias, G | 1 |
| Boumpas, DT | 1 |
| Junga, Z | 1 |
| Stitt, R | 1 |
| Tracy, C | 1 |
| Keith, M | 1 |
| Cohen, EM | 1 |
| D'Silva, K | 1 |
| Kreps, D | 1 |
| Son, MB | 1 |
| Costenbader, KH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Optimization of Glucocorticoid Taper Strategies for Maintenance Therapy of Systemic Lupus Erythematosus Associated Immune Thrombocytopenia (SLE-ITP)[NCT05506033] | 120 participants (Anticipated) | Interventional | 2022-08-15 | Enrolling by invitation | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for hydroxychloroquine and Macrophage Activation Syndrome
| Article | Year |
|---|---|
Macrophage activation syndrome as an unusual presentation of paucisymptomatic severe acute respiratory syndrome coronavirus 2 infection: A case report.
Topics: Adolescent; Blood Chemical Analysis; Ceftriaxone; China; Clinical Laboratory Techniques; Coronavirus | 2020 |
Update οn the diagnosis and management of systemic lupus erythematosus.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Humanized; Autoantibodies; Azathioprine; Calc | 2021 |
3 other studies available for hydroxychloroquine and Macrophage Activation Syndrome
| Article | Year |
|---|---|
Systemic lupus erythematosus associated with development of macrophage activation syndrome and disseminated aspergillosis.
Topics: Adrenal Cortex Hormones; Adult; Aspergillosis; Female; Humans; Hydroxychloroquine; Lupus Erythematos | 2023 |
Novel use of rituximab in macrophage activation syndrome secondary to systemic lupus erythematosus.
Topics: Antineoplastic Agents, Immunological; Antirheumatic Agents; Diagnosis, Differential; Etoposide; Fema | 2017 |
Arthritis and use of hydroxychloroquine associated with a decreased risk of macrophage activation syndrome among adult patients hospitalized with systemic lupus erythematosus.
Topics: Adolescent; Adult; Arthritis; Case-Control Studies; Female; Hospitalization; Humans; Hydroxychloroqu | 2018 |